1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Biopharma’s Must-Know Q4 Catalysts

 
• By Elizabeth Cairns

Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too.   

The leaves are changing color and the nights drawing in – but what will the final season of the year bring for biopharma? Here, Scrip compiles the major clinical readouts that are on the way, and companies including Sanofi, Novartis AG and AstraZeneca PLC stand to gain – or lose.

Key Takeaways
  • Cytokinetics’ aficamten has huge sales forecasts, and a hit in Phase III will be a prerequisite for realising these

The table below considers ten products with highly significant clinical readouts coming in the final months of the year. It...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D